Processing...
All Trials
Search
Search
There are 1601 active trials in our database.
Click on a trial to see more information.
1601 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with unresectable stage III/IV or metastatic melanoma (cutaneous/acral; plus a cohort for mucosal or uveal), ECOG 0–1, progressed after at least one standard systemic therapy (e.g., anti–PD-1/L1; BRAF±MEK if BRAF V600-mutant), with an accessible lesion for harvest and stable treated brain metastases allowed. Patients undergo tumor resection for manufacturing, lymphodepleting cyclophosphamide/fludarabine, then a single infusion of autologous CD40L-augmented tumor-infiltrating lymphocytes (CD40 ligand signaling to enhance APC activation/costimulation) followed by short-course bolus aldesleukin (IL-2) support.
ClinicalTrials.gov ID: NCT06961357
TrialFetch AI summary: Adults (≥18) with measurable advanced/metastatic soft tissue sarcoma with intact Rb protein expression (phase 1: any STS after ≥1 prior systemic therapy; phase 2: advanced/metastatic leiomyosarcoma or dedifferentiated liposarcoma where gemcitabine/docetaxel is standard, no prior gemcitabine) are treated with a sequential regimen of oral abemaciclib (CDK4/6 inhibitor enforcing Rb-mediated G1 arrest) followed by IV gemcitabine timed to cell-cycle re-entry. In phase 2, this sequence is randomized against standard gemcitabine plus docetaxel, with cross-over allowed at progression.
ClinicalTrials.gov ID: NCT06498648
TrialFetch AI summary: Adults with measurable locally advanced/metastatic rare non-urothelial GU malignancies (pure urinary-tract adenocarcinoma or squamous cell carcinoma) or treatment-refractory testicular germ cell tumors (ECOG 0–1; germ cell tumors must have exhausted curative options) receive enfortumab vedotin, a nectin-4–directed antibody–drug conjugate delivering MMAE (microtubule-disrupting payload), either alone (D1/8/15 q28d) or—if checkpoint inhibitor–naïve—in combination with pembrolizumab (anti–PD-1) (EV D1/8 + pembrolizumab D1 q21d). Prior PD-1/PD-L1 therapy is allowed in separate cohorts, but prior EV/MMAE-ADC exposure is excluded.
ClinicalTrials.gov ID: NCT06041503
TrialFetch AI summary: Adults with HER2-negative metastatic breast cancer (including triple-negative) and liver-dominant measurable metastases (≤50% liver involvement, limited extrahepatic disease; ECOG 0–1) who have progressed on endocrine therapy + CDK4/6 if HR+ and generally after/unsuitable for a topo-1 payload ADC are randomized to liver-directed induction with melphalan via hepatic arterial infusion using the Melphalan/HDS extracorporeal filtration system (DNA-alkylating/crosslinking agent; aims to boost intrahepatic exposure while limiting systemic toxicity) for up to 2 cycles followed by single-agent chemotherapy (eribulin, vinorelbine, or capecitabine) vs the same physician’s-choice single-agent chemotherapy alone. Primary outcome is hepatic progression-free survival.
ClinicalTrials.gov ID: NCT06875128
TrialFetch AI summary: Adults with locally confirmed IDH1 R132–mutated hematologic malignancies (including AML and MDS) or non-glioma solid tumors who have moderate/severe hepatic impairment or severe renal impairment (with matched adequate-function control cohorts) receive once-daily oral ivosidenib, a mutant IDH1 inhibitor that lowers 2-hydroxyglutarate and promotes differentiation. Azacitidine co-treatment is allowed for hematologic malignancies, and prior/ongoing ivosidenib may be permitted in select cases.
ClinicalTrials.gov ID: NCT07006688
TrialFetch AI summary: Adults with biopsy-proven advanced hepatocellular carcinoma (or LI-RADS 5) who are not candidates for curative/locoregional therapy or have progressed after it (ECOG 0–2; Child-Pugh A or B7; measurable disease) receive dose-escalated triple therapy with sorafenib (oral multikinase/VEGFR pathway inhibitor) plus sonidegib (oral Hedgehog pathway SMO inhibitor) plus irinotecan (IV topoisomerase I inhibitor). This single-arm study determines the maximum tolerated dose over 32 days with AI/phenotypic and ctDNA-informed individualized dosing; UGT1A1*28 homozygotes are excluded.
ClinicalTrials.gov ID: NCT05669339
TrialFetch AI summary: For adults with unresectable/metastatic melanoma with biopsy-confirmed liver metastasis who are systemic-treatment naïve in the metastatic setting (prior adjuvant anti–PD-1 and/or BRAF/MEK allowed if >6 months), this study combines liver-directed melphalan percutaneous hepatic perfusion via the HEPZATO KIT (temporary hepatic vascular isolation with extracorporeal filtration to limit systemic exposure) with fixed-dose Opdualag (nivolumab PD-1 blockade plus relatlimab LAG-3 blockade to enhance T-cell activation). It evaluates safety and preliminary systemic and hepatic antitumor activity.
ClinicalTrials.gov ID: NCT07281924
TrialFetch AI summary: For adults (18–<80) with symptomatic, biopsy-proven pleural malignancy including pleural mesothelioma with pleural effusions refractory to available standard therapies and adequate performance status/organ function, this study tests locally manufactured autologous “Fast TILs” (pleural effusion–derived pleural-infiltrating T cells expanded ex vivo to enrich tumor-reactive T cells) given as a one-time intrapleural infusion after outpatient lymphodepleting chemotherapy. Patients then receive short-course low-dose intrapleural IL-2 to support T-cell activation and persistence.
ClinicalTrials.gov ID: NCT07192900
TrialFetch AI summary: Eligible patients are adults with newly diagnosed, measurable metastatic pancreatic ductal adenocarcinoma and good performance status (ECOG 0–1) who have not received prior chemotherapy for metastatic disease (prior adjuvant/perioperative gemcitabine allowed if completed ≥6 months before metastasis). Treatment is single-arm pegcetacoplan (a proximal complement C3 inhibitor) added to first-line mFOLFIRINOX given q14 days for up to 8 cycles, evaluating safety plus preliminary antitumor and thromboembolism-reduction signals.
ClinicalTrials.gov ID: NCT07214298
TrialFetch AI summary: Enrolling adult men with progressive metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1) on continuous ADT with castrate testosterone, including bone-only disease, with no prior 177Lu-PSMA-617 or sipuleucel-T. Participants are randomized to PSMA-targeted radioligand therapy 177Lu-PSMA-617 (beta-emitting lutetium-177 delivering radiation to PSMA-expressing cells) IV every 6 weeks for up to 6 cycles versus the same regimen plus sipuleucel-T (autologous PAP–GM-CSF–activated cellular immunotherapy) given every 2 weeks for 3 doses starting around week 8.
ClinicalTrials.gov ID: NCT07219147